Axxcess Wealth Management LLC Purchases 1,697 Shares of Natera, Inc. (NASDAQ:NTRA)

Axxcess Wealth Management LLC grew its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 119.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,122 shares of the medical research company's stock after purchasing an additional 1,697 shares during the period. Axxcess Wealth Management LLC's holdings in Natera were worth $441,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of NTRA. Price T Rowe Associates Inc. MD grew its stake in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Norges Bank bought a new stake in Natera during the 4th quarter worth approximately $224,040,000. Vanguard Group Inc. grew its position in Natera by 7.7% during the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after acquiring an additional 439,778 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Up 0.4%

NASDAQ:NTRA traded up $0.58 during trading hours on Monday, hitting $161.01. 102,656 shares of the stock were exchanged, compared to its average volume of 1,417,929. The company's 50 day moving average is $161.05 and its two-hundred day moving average is $158.41. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The company has a market capitalization of $21.99 billion, a P/E ratio of -109.53 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business's revenue for the quarter was up 36.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.56) EPS. On average, equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on NTRA. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. UBS Group increased their price target on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Piper Sandler increased their price target on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Finally, Barclays increased their price target on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $184.63.

Insider Activity

In other news, Director Gail Boxer Marcus sold 4,299 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the transaction, the director owned 8,118 shares of the company's stock, valued at $1,358,628.48. This represents a 34.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $157.07, for a total value of $471,210.00. Following the completion of the transaction, the insider directly owned 133,205 shares in the company, valued at approximately $20,922,509.35. This trade represents a 2.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,272 shares of company stock valued at $8,345,368 in the last 90 days. 7.60% of the stock is owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.